Moderna, Inc. MRNA

Moderna stock rose 7% to about $195 on Sept. 24 as investors eye intismeran autogene's Phase 3 melanoma data due at the ESMO Congress on Oct. 24. The personalized cancer vaccine, developed with Merck, already met its primary endpoint of recurrence-free survival and a key secondary endpoint of distant metastasis-free survival in resected melanoma when combined with Keytruda, though survival curves haven't been released. Analysts have become more constructive after August readouts, though overall targets remain well below the current price: a mean target around $120, with the highest at $170. Moderna has framed itself as an mRNA platform company with oncology at the center, not a COVID vaccine business. The company disclosed three abstracts for ESMO; the presidential symposium slot signals a practice-changing readout if data are favorable. Still, the market has priced in a positive outcome prior to hazard ratios, and data disclosure on Oct. 24 remains pivotal. A strong ESMO readout could materially shift Moderna's oncology platform trajectory and investor sentiment.

Moderna (MRNA) closed at $198.88, up 2.08% on the session, outperforming the S&P 500 (+0.51%), Dow (+0.93%), and Nasdaq (+0.48%). Over the past month, MRNA has surged about 36.5%, topping the Medical sector's 3.4% decline and the S&P's 0.7% gain. Anticipation builds ahead of the next earnings release: the company is expected to report an EPS of -$1.36 (down about 166.7% YoY) and revenue of $888.78 million (down ~12.5%). For the full year, Zacks consensus calls for -$8.50 per share on $2.11 billion in revenue (roughly -17% EPS, +8% revenue). Analyst estimates have been nudged higher by about 1.42% in the past month. Moderna holds a Zacks Rank of #3 (Hold), with the Medical - Biomedical & Genetics group ranking in the bottom third of industries. Near-term earnings decline and modest revisions suggest a moderate, not transformative, impact.

Moderna stock climbed to a four-year high after news it is exploring investment opportunities in the UAE, with Chairman Noubar Afeyan meeting UAE officials to discuss collaboration on research, development and expanding local manufacturing capabilities. The talks aim to deepen the US-UAE strategic partnership and diversify Moderna's revenue by expanding its footprint in the Middle East. Separately, investors await updated data from Moderna’s INTERPATH-001 trial of intismeran autogene with Merck's Keytruda for melanoma, to be presented at the ESMO Congress 2026 in Madrid. The Phase 3 readouts have shown recurrence-free survival and distant metastasis-free survival benefits. Hedge fund positions in Moderna remained sizable in Q2, even as some funds exited; investors are watching whether the UAE deal and ongoing oncology programs can meaningfully impact long-term growth. UAE investment talks and regional expansion could significantly diversify Moderna's revenue and influence its growth trajectory.

Moderna’s stock has surged in a two-month rally that began mid-August after late-stage results for its cancer vaccine INTerpath-001 in melanoma, developed with Merck. From about $63 on Aug 18, shares vaulted to a fresh 52-week high near $195.71 and settled around $195. The rally followed the Phase 3 readout showing vaccine plus Keytruda beat Keytruda alone at preventing recurrence and spread, Moderna’s first late-stage cancer-vaccine win. CEO Stéphane Bancel underscored Moderna is not a COVID-only company, noting five approved vaccines, two launches this year, and a 50/50 oncology franchise with Merck. Earlier in August, FDA approved mFLUSIVA, Moderna’s mRNA flu shot for adults 50 and older. Moderna is pursuing broader intismeran trials in stage I lung cancer and early bladder cancer, with readouts anticipated later this year. A constraint cited is hospitals, not dose. Positive INTerpath-001 data and pivot beyond COVID could materially alter Moderna's growth trajectory and investor sentiment.

Moderna's CEO Stéphane Bancel outlines next moves after a breakthrough cancer vaccine and weighs the broader pharma landscape. He frames the company’s strategy around regulatory clarity, accelerating R&D with AI, and expanding global access while managing rising competition from China. He also discusses the state of the FDA and readiness for bioterrorism, signaling a focus on both policy navigation and national security dimensions of biotech. The interview situates Moderna within a fast-changing industry where AI, manufacturing scale, and geopolitical risk shape execution of its cancer vaccine program and other pipelines. Overall, messaging emphasizes resilience and rapid innovation to maintain a leadership position despite headwinds. Breakthrough vaccine milestone plus emphasis on regulatory, competitive, and AI-driven strategy signals meaningful influence on Moderna's trajectory.

Moderna CEO Stéphane Bancel said Moderna has 'never been' a COVID-19 vaccine company, highlighting its broader mRNA platform focused on treating multiple diseases. The company aims growth across three areas—vaccines, oncology, and rare diseases—and is pushing a personalized mRNA cancer therapy, Intismeran Autogene, developed with Merck, into Phase 3 with data due at the ESMO Congress in October. Separately, Twilio is viewed as a beneficiary of AI-driven communication demand, with Morgan Stanley calling it best exposed to higher volumes from AI agents and TD Cowen lifting its price target to 300 from 260. The stock reaction mirrored investor enthusiasm, with TWLO up about 2% to the highest level since November 2021 and MRNA up roughly 1% to the highest level since January 2023, as market selloffs persisted. Retail sentiment on Stocktwits remained bullish. Broader mRNA platform expansion and oncology/rare-disease pipeline could meaningfully diversify Moderna's growth beyond vaccines.

Moderna plans to file a biologics license application for intismeran, its personalized mRNA cancer vaccine developed with Merck, after a Phase 3 melanoma trial met its primary endpoint and distant metastasis-free survival at interim analysis. The companies will focus on regulatory filing first; intismeran is being studied in additional cancers including lung, renal cell carcinoma, bladder, pancreatic and gastric cancers, with Moderna and Merck coordinating hospital logistics and a shared platform to support individualized manufacturing and delivery. Moderna also bullish on off‑the‑shelf cancer vaccines, autoimmune and rare‑disease programs, with propionic acidemia pivotal data expected by year‑end. CEO Stéphane Bancel framed Moderna as an mRNA platform company expanding beyond COVID, with a broader pipeline and AI‑driven development. Positive Phase 3 results and imminent biologics license application for intismeran could become a major growth catalyst by expanding beyond COVID vaccines.

Moderna co-founder Bob Langer has joined Cellular Intelligence’s scientific advisory board, linking Moderna’s mRNA expertise to an AI-driven drug development network. Cellular Intelligence recently acquired a Parkinson’s cell therapy program, adding external AI-driven discovery to neurology research. Langer’s advisory role deepens Moderna’s connections to AI medicine collaborations and a broader ecosystem that could support pipeline diversification beyond vaccines and oncology. Analysts suggest the arrangement underscores Moderna’s core narrative: using AI and analytics to boost R&D productivity, while potential wins from AI-enabled development would be watched in upcoming updates, trial designs, or external partnerships. The coverage notes a major warning sign for Moderna, and places the stock within a broader set of healthcare AI exposures around 37 related names. Moderna’s market cap is around $69 billion; investors will monitor concrete AI-enabled milestones. External AI collaborations and Langer's advisory role could modestly influence Moderna's R&D and investor sentiment, without guaranteeing near-term revenue impact.

Moderna’s stock has surged over the past year, putting scrutiny on whether the share price reflects sales prospects or just momentum. On a price-to-sales basis, MRNA trades at about 32.7x, far above biotech peers (roughly 12.8x) and a closer group (~6.8x), implying investors are paying a premium for potential future revenue. Even with the mFlusiva flu vaccine launch and growing interest in mRNA and AI in medicine, a tailored model suggests a fair multiple well below the current level, penalizing recent losses and perceived sales risk. Analysts’ broader views on future revenue mix—such as Europe patent decisions and the durability of Moderna’s sales base—could influence the stock’s appeal. Community narratives on Simply Wall St flag scenarios where the shares appear overvalued or undervalued, underscoring valuation uncertainty amid warnings. The piece emphasizes this is fundamental analysis, not investment advice. Major product launch and regulatory/patent developments could materially alter revenue trajectory and investor sentiment, justifying a 4.

BioNTech (BNTX) faced a setback in colorectal cancer with autogene cevumeran, an mRNA cancer vaccine, as Phase 2 results led an independent review to end the trial, citing an unlikely improvement in efficacy and an apparent imbalance in overall survival. Autogene cevumeran remains in Phase 2 studies for pancreatic ductal adenocarcinoma. In a separate development, BioNTech reported Phase 3 stage 1 data for Gotistobart in NSCLC showing a median overall survival of 18.5 months versus 10 with docetaxel in 87 patients, though the pivotal stage 2 is ongoing. Moderna’s Phase 3 melanoma vaccine trial data mark a milestone for personalized mRNA cancer vaccines and could lift sentiment for the space. BioNTech also has BNT113 for HPV16-positive head and neck cancer in Phase 2/3 with FDA Fast Track designation. Investors will closely watch upcoming mid- and late-stage results. A Moderna melanoma vaccine Phase 3 win could materially boost investor expectations for Moderna's oncology portfolio and the broader mRNA cancer vaccine space.

Moderna stock jumped about 510% in the year to Sept. 21, 2026, from roughly $25 to $173, outpacing the market. The spike centered on August 19, 2026, when Merck and Moderna announced that their Phase III melanoma vaccine trial, intismeran autogene, met endpoints for recurrence-free and distant metastasis-free survival. The result followed earlier signals: 2024 Phase II data in adjuvant melanoma and a 2025 update that the trial with KEYTRUDA was fully enrolled. Even as Spikevax sales declined and Moderna cut about 10% of its workforce in 2025, management kept funding the cancer program, with Merck bearing half the cost. The interim CMV vaccine data served as a reminder that trials can disappoint. The melanoma outcome was a catalyst, and the question now is FDA approval and commercial potential. Phase III melanoma endpoints and cost-sharing with Merck create a meaningful inflection toward oncology that could materially alter Moderna's growth trajectory.

Moderna’s stock sits near multiyear highs around $157 after a wave of mRNA‑driven drug news broadens beyond COVID vaccines. Phase 3 INTerpath-001 data for Instimeran Autogene (co-developed with Merck) plus Keytruda showed meaningful improvements in recurrence-free survival and distant metastasis-free survival in completely resected Stage IIB–IV melanoma, triggering a 177% jump in late August. Yet most analysts remain cautious, with Barron’s noting a neutral/hold consensus and two downgrades following the rally. Rothschild & Co. Redburn cut to sell, citing overreaction and uncertainty about nine other trials. J.P. Morgan’s Jessica Fye warns subsequent trial results are still uncertain and that the immediate economic impact appears baked in. Moderna has also raised about $2.6 billion via convertible debt at $210.58 per share, risking dilution. Absent more trial news, investors may take profits and wait for a clearer oncology pivot. Convertible debt issuance and mixed trial data create near-term downside risk and potential dilution that could materially affect Moderna's trajectory.

Moderna (MRNA) is rallying as investors position ahead of late-October data from INTerpath-001, its melanoma trial with Merck's Keytruda. The 1,137-patient study tested intismeran autogene in high-risk melanoma post-surgery and reportedly met its primary recurrence-free survival endpoint and a key secondary distant metastasis-free survival endpoint, though numerical details were not disclosed. Detailed Phase 3 results are slated for an October 24 presentation at the ESMO Congress Presidential Symposium, reserved for potentially practice-changing readouts. A positive top-line could confirm a durable neoantigen-driven response and bolster the program across other tumors; a weaker signal could compress the stock's 2026 rally. The move appears to be an intismeran-specific bet rather than a broad re-rating of the mRNA platform, with BioNTech underperforming this year. Upcoming ESMO Phase 3 results for intismeran autogene could either validate a durable melanoma benefit or trigger a sharp correction.

Moderna stock surged about 12% to a 52-week high as investors digest news that detailed data from the INTerpath-001 phase III trial of intismeran autogene, Moderna's personalized mRNA cancer therapy developed with Merck, will be unveiled at the ESMO Congress next month. The Presidential Symposium on Oct. 24 will present results beyond the topline findings reported last month, which showed statistically significant improvements in recurrence-free survival and distant metastasis-free survival in high-risk, resected melanoma when intismeran was combined with Merck's Keytruda. If the full data confirm durable benefit, the program could validate the personalized mRNA approach and support expansion into other cancers across nine studies, including NSCLC, bladder cancer and renal cell carcinoma. Beyond melanoma, oncology could become a major long-term driver and help diversify Moderna's revenues away from seasonal vaccines, with potential commercial launch as early as next year if approved. INTerpath-001 data and broader oncology pivot could materially shift Moderna's growth trajectory.

Moderna stock rose 12% to $173 after Phase 3 data for its personalized cancer vaccine intismeran autogene showed strong melanoma results and earned a spot in ESMO’s Presidential Symposium on October 24. The INTerpath-001 trial compares intismeran autogene plus Merck’s Keytruda against Keytruda alone in resected melanoma, with Moderna claiming a meaningful adjuvant benefit. Three abstracts on the therapy were accepted for Madrid, but only one made the Presidential Symposium. The data could redefine how oncologists treat multiple tumors, per Moderna. Separately, FDA clearance of updated Spikevax and mNEXSPIKE boosters targeting the XFG variant reinforced the respiratory franchise ahead of flu season. Analysts’ mean target sits at $120, about 31% below the close, while coverage has thinned and the stock sits near its 52-week high after a rally from mid-2025. Two major catalysts—ESMO melanoma data potentially surpassing Keytruda in adjuvant melanoma and FDA vaccine clearances—could substantially alter Moderna's trajectory and investor sentiment.

Moderna stock surged to a fresh three-year high, trading near $174 after hitting an intraday peak of $176.86, ahead of two health conferences this week. The company will present Phase 3 INTerparth-001 data for intismeran autogene, in combination with Merck's Keytruda, at Bernstein Insights: Healthcare Leaders and Disruptors and at the ESMO Congress 2026 in Madrid. The trial met its primary endpoint of recurrence-free survival and the key secondary endpoint of distant metastasis-free survival, marking the first meaningful Phase 3 readout for an INT and mRNA cancer therapy combo and suggesting potential superiority over Keytruda alone. Moderna emphasizes a large melanoma market, citing US and global incidence. Hedge funds reportedly increased aggregate holdings to about $1.5 billion in Q2, despite some exits, signaling rising investor conviction ahead of potential uptake. Phase 3 success for the combination therapy and upcoming presentations could materially bolster Moderna's oncology prospects and investor sentiment.

Moderna's Intismeran, developed with Merck's Keytruda, showed significant improvements in recurrence-free survival and distant metastasis-free survival in the INTerpath-001 Phase 3 trial for high-risk melanoma after tumors were surgically removed. Detailed results will be presented at the European Society for Medical Oncology (ESMO) Congress 2026 in a Presidential Symposium on Oct. 24, marking the first full data release from the pivotal study. Moderna is evaluating the therapy across other cancers, including lung, kidney, and bladder cancer. The news followed a prior landmark win and sent Moderna's shares higher, although retail sentiment on Stocktwits remains mixed. Positive Phase 3 melanoma data and upcoming presentation could significantly alter Moderna's oncology potential and market perception.

Moderna announced three abstracts on intismeran autogene, an investigational mRNA-based neoantigen therapy, for the adjuvant treatment of resected stage IIB-IV melanoma, accepted for presentation at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid. A Phase 3 study (INTerpath-001) will be presented in a Presidential Symposium comparing intismeran autogene plus pembrolizumab versus pembrolizumab alone. Poster presentations include Adjuvant intismeran autogene plus FOLFIRINOX in resectable pancreatic ductal adenocarcinoma (Phase I results) and INTerpath-014: a Phase 3 study of adjuvant intismeran autogene plus subcutaneous pembrolizumab or intisimeran monotherapy versus placebo in completely resected high-risk stage I NSCLC. Intismeran autogene is co-developed by Moderna and Merck (MSD). Moderna will host a live investor webcast on Saturday, October 24, at 7:00 PM CEST / 1:00 PM EDT, with a replay available afterward. Moderna notes its mRNA platform underpins vaccines and therapeutics across diseases. Phase 3 melanoma adjuvant data plus additional Phase 3-leaning abstracts indicate meaningful near-term pipeline value and investor interest in Moderna's cancer vaccine platform.

Moderna (MRNA) stock jumped about 9.4% after Phase 3 INTerpath-001 results showing potential in its personalized cancer vaccine intismeran autogene when used with Merck’s Keytruda for high-risk melanoma. The move extended momentum from the trial data rather than new disclosures, aided by Wall Street upgrades from Argus and Bank of America. Regulatory sentiment improved after FDA approved Moderna’s updated 2026-2027 COVID vaccines, while a $2.6 billion convertible note offering completed in late August funds ongoing oncology development. The shares are highly volatile, with 57 moves greater than 5% in the last year. The stock is up about 442% YTD and near its 52-week high of $174.38. Four days earlier, a Morgan Stanley conference press boosted sentiment around the vaccine pipeline. Investors who bought $1,000 of Moderna five years ago would have about $385.10 today. Phase 3 data and regulatory updates provide momentum but do not fundamentally alter Moderna's long-term trajectory.

Moderna jumped about 9% to roughly $168 after announcing its Phase 3 adjuvant melanoma study for intismeran autogene earned a Presidential Symposium slot at the European Society for Medical Oncology congress in Madrid. No new efficacy data accompanied the news; the Presidential Symposium is the event’s highest-profile platform, signaling organizers expect the dataset to be practice-changing. Merck rose about 1% and BioNTech 2% on read-through, underscoring a Moderna-specific rerating rather than a broad mRNA oncology endorsement. Moderna will present the dataset and host a webcast on Oct. 24; investors should watch whether the stock holds around $167 into the close as event risk persists. Presidential Symposium slot signals potential favorable re-rating for Moderna without new efficacy data.

Moderna is highlighted among three bullish setups after a mid-August surge driven by Phase 3 data showing its mRNA cancer therapy significantly reduces melanoma recurrence. With melanoma affecting more than 2% of Americans, the therapy is portrayed as having blockbuster potential due to a large total addressable market. Shares are described as consolidating in a high-tight flag pattern on low volume, suggesting bulls are holding and a new move higher could follow. The piece groups Moderna with SanDisk and Coinbase as stocks forming constructive base structures, arguing that consistent weekly screening can reveal such setups. Overall, Moderna is presented as a high-potential but uncertain growth story within a broader market idea. Phase 3-positive data and a large TAM imply potential substantial upside, though success depends on regulatory and real-world adoption.

Moderna (MRNA) shares rise sharply on positive developments tied to its core vaccine and mRNA pipeline. Share surge signals major strategic or product news likely to shift near-term trajectory and sentiment.

Moderna stock undergoes another major move amid signs that interest in its cancer vaccine program may be reviving. Cancer vaccine program represents major product innovation that can substantially shift company trajectory and investor sentiment.

Moderna shares rise 6% as cancer vaccine gains extend to 137% for the month. BioNTech and Novavax post modest increases. Cancer vaccine momentum drives substantial stock gains and signals major future growth for Moderna.

Moderna may face challenges by 2026 that could create investment or strategic opportunities amid broader market pessimism. Speculation on 2026 outlook points to moderate influence on future performance and sentiment without major immediate shifts.

Moderna investigates cancer treatments as potential turnaround after COVID vaccine revenue declines, focusing on mRNA-based oncology programs to drive future growth. Cancer programs mark major strategic expansion that could reshape Moderna's long-term pipeline and investor outlook.

Moderna achieved historic success with its COVID vaccine, with its cancer vaccine positioned for potentially even greater impact on future growth. Positive cancer vaccine prospects could significantly alter Moderna's long-term trajectory and investor outlook.

Moderna achieves success with its cancer vaccine, spurring expanded development across multiple tumor types. Cancer vaccine success drives major oncology expansion and revenue potential for Moderna.

Moderna encounters major obstacles in commercializing mRNA cancer vaccines, including regulatory hurdles, manufacturing scale-up difficulties, clinical efficacy validation, and competition that could delay market entry and limit revenue potential. Barriers to mRNA cancer vaccine commercialization threaten to delay Moderna's pipeline expansion and reduce long-term growth prospects.

Moderna leverages AI to speed cancer vaccine development and advance next-generation mRNA medicines targeting oncology and other diseases. AI-driven cancer vaccine programs represent major strategic R&D moves with potential to significantly shift Moderna's long-term pipeline and investor outlook.